---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-001672"
form_type: "8-K"
ticker: "ZSQR"
cik: "0001759186"
company_name: "Z Squared Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:33:49.703232+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Coeptis Therapeutics restates 2022 annual and 2023 quarterly financials; prior reports no longer reliable

## Summary
- Audit committee determined 2022 audited and 2023 quarterly financials are unreliable due to accounting errors.
- Unrecorded liability from October 2022 merger must be booked; remaining balance immaterial and payable in 2024.
- Reimbursement commitment under a January 2023 research agreement requires restatement for Q1-Q3 2023.
- Company will file restated financial statements as soon as practicable.
- Previously disclosed material weaknesses in internal controls; new CFO hired to improve processes.

## SEC filing metadata
- accession: 0001683168-24-001672
- form_type: 8-K
- ticker: ZSQR
- cik: 0001759186
- company_name: Z Squared Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759186/000168316824001672/0001683168-24-001672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759186/000168316824001672/coeptis_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-001672
- JSON: https://secwatch.observer/filing/0001683168-24-001672.json
- Plain text: https://secwatch.observer/filing/0001683168-24-001672.txt

## Key facts
- Auditor Changes
  Z Squared Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  - Auditor: Turner, Stone & Company, L.L.P.
  source text: On March 19, 2024, the Audit Committee of Coeptis Therapeutics Holdings, Inc. (“the Company”), after discussions with Management, determined that, due to certain accounting errors described below, the following may no longer be relied upon: (i) the audited consolidated financial statements for the year ended December 31, 2022, included in the Company’s Form 10-K for the year ended December 31, 2022; (ii) the unaudited condensed consolidated financial statements for the periods ended March 31, June 30, and September 30, 2023, included in the Company’s Forms 10-Q for the periods then ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316824001672/0001683168-24-001672-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.